Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est
Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
Share
Why It Matters
Starling Oncology made its sales forecast smaller for next year. This shows the company is being more careful about its growth plans.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.